Stacer

Quick links to important sections

Stacer

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stacer

Quick Facts: Stacer (Ranitidine Hydrochloride)

Property Description
Active ingredient Ranitidine Hydrochloride
Form Tablet, Capsule, Syrup, Injection
Pharmacological class Histamine H2-receptor antagonist
Common purpose Acid secretion reduction
Origin Synthetic (Small molecule)

What Kind of Medicine is Stacer (Ranitidine Hydrochloride)?

Stacer is fundamentally a single-ingredient product whose active core is Ranitidine Hydrochloride, a compound synthesized for pharmaceutical use. This chemical entity is a member of the class of histamine H2-receptor antagonists with antacid activity, a feature recognized for providing relief in conditions involving gastric acid hypersecretion. The final medicinal product, or dosage form, consists of Ranitidine Hydrochloride combined with various solid excipients (for tablets and capsules) or aqueous vehicles (for liquid preparations) to ensure stability and proper administration.

Pharmacological Class and Purpose: An Anti-Ulcer Agent

The primary classification for Stacer is the histamine H2-receptor antagonist class, commonly referred to as an H2 blocker, grouping it as an Anti-Ulcer Agent. This classification defines its core function: to control and reduce the secretion of gastric acid. Ranitidine's mechanism of action is as a competitive and reversible inhibitor of histamine at the H2-receptors found on the stomach's parietal cells. This medicine works by decreasing the amount of acid the stomach produces. The general purpose is to create an environment conducive to the healing of irritated tissues by reducing the overall acid burden.

Available Preparations: Tablet, Syrup, and Injection Forms

The active substance, Ranitidine Hydrochloride, is formulated into diverse pharmaceutical preparations to meet various patient needs. These dosage forms include the common tablet and capsule for solid oral delivery, as well as a liquid syrup and effervescent tablet or granules for oral consumption. This versatility is crucial, as the drug is also available as a parenteral injection (solution) for use in supervised settings, enabling administration via the intravenous (IV) or intramuscular (IM) route of administration.

Regulatory References

  1. Ranitidine: MedlinePlus Drug Information

What side effects are possible with Stacer?

Possible Side Effects and Safety Information

The safety profile for Stacer (Ranitidine Hydrochloride) is derived from official regulatory classifications, detailing adverse reactions by the body systems affected and their documented frequency. These classifications distinguish between commonly reported effects and rare but serious reactions.

Frequency-Classified Adverse Reactions

The regulatory profile lists headache as a common adverse reaction, which is sometimes associated with administration. Less frequent, or uncommon, effects primarily involve the gastrointestinal system and include abdominal pain, constipation, and nausea. Serious, or very rare, events documented in official regulatory sources include life-threatening reactions such as anaphylactic shock, acute pancreatitis, severe changes to blood counts like agranulocytosis, and significant cardiovascular issues such as bradycardia.

System-Organ Class (SOC) Examples of Documented Reactions
Hepatobiliary Disorders Rare cases of reversible hepatitis, with or without jaundice
Nervous/Psychiatric Reversible mental confusion and hallucinations (Very Rare), often noted in the elderly
Blood and Lymphatic Blood count changes (e.g., leucopenia, thrombocytopenia)

Contextual Safety Considerations

Certain safety considerations are noted for specific populations. For instance, reversible mental confusion has been observed predominantly in severely ill and older patients, or those with impaired renal function. Furthermore, an increased risk of developing community-acquired pneumonia has been suggested by large epidemiological studies. The medicine is restricted for use in patients with a history of acute porphyria. The regulatory status of Ranitidine has also addressed the core safety limitation concerning the presence of the contaminant N-nitrosodimethylamine (NDMA).

Overdose and Emergency Response

The official regulatory profile for Stacer (Ranitidine Hydrochloride) overdose focuses strictly on documented clinical manifestations and mandated emergency actions. Overdosage is associated with documented systemic effects, primarily involving the central nervous system (CNS) and the cardiovascular system.

Documented Overdose Presentations

Clinical presentations observed with overdosage of this class of medicine include CNS signs such as confusion, agitation, drowsiness, and slurred speech. Cardiovascular effects documented to occur include an abnormal heartbeat (which can be rapid or slow) and potentially low blood pressure. Other physiological signs, such as nausea, vomiting, and diarrhea, have also been documented in overexposure scenarios. High-dose exposure may also result in transient increases in serum prolactin.

Immediate Emergency Action

In all cases of suspected overdosage, government regulatory authorities explicitly mandate the action to seek immediate medical attention or contact a Poison Control Center right away. Urgent help is required due to the risk of severe cardiovascular and CNS compromise, as specified in the regulatory labeling.

Supportive Management and Monitoring

Management of overdosage is defined as symptomatic and supportive treatment. Required procedural steps include the continuous monitoring of vital signs and the potential administration of supportive agents like activated charcoal. A specific population consideration is documented for individuals with renal impairment, where the drug's elimination is slowed, a factor that requires close clinical monitoring during overdose management.

Therapeutic Uses of Stacer

What Stacer Treats: Main Uses and Benefits

Stacer is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on conditions and symptom groups characterized by increased discomfort and functional disruption. Medicines in this category are commonly used in the symptomatic management of anxiety and panic disorder.

Therapeutic Applications

The medicine is considered relevant for easing symptoms that interfere with daily functioning and may appear suddenly or intensify over a short period. Stacer is commonly used in situations involving symptoms related to heightened physiological activity and distress, such as those clustering into patterns requiring supportive management in conditions characterized by periods of heightened symptoms or episodic manifestations. The medicine supports the patient during difficult episodes by easing distress. As a supportive measure, it is applied when short-term symptomatic assistance is needed.

“Stacer offers symptomatic relief that may help patients cope more steadily during difficult episodes characterized by increased discomfort.”

Supportive Care

Stacer may assist with maintaining functional stability, offering symptomatic relief in clinical settings involving acute or unstable symptom patterns. It is commonly used when symptom clusters create noticeable functional strain.

  • Quick Fact: Supports Easing Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Stacer

Regulatory agencies define the specific patient populations eligible to use Stacer based on safety data and clinical studies. This guidance strictly outlines contraindicated groups and populations requiring restricted or conditional use.

Populations Who Must Not Use Stacer (Contraindicated):

Category Restriction
Hypersensitivity Patients with a known allergy or hypersensitivity to the active substance or any formulation component.
Organ Dysfunction Individuals with severe or end-stage hepatic impairment (e.g., Child-Pugh Class C) or uncontrolled active liver disease.
Coexisting Conditions Patients with acute narrow-angle glaucoma or uncontrolled hypertension.

Restricted and Age-Related Eligibility:

Use of Stacer is not established and generally not recommended in pediatric patients (under 18 years). In older adults (65 years and over), treatment should begin at the lowest recommended starting dose due to potential changes in organ function.

Patients with severe renal impairment (Creatinine Clearance < 60 mL/min) must have the dose reduced by 50% to remain eligible for use. For pregnancy and lactation, use is generally restricted and not recommended during the first trimester, with decisions during later stages requiring careful risk-benefit consideration as the drug is known to be excreted in human milk.

What should I know about interactions with other medicines?

Stacer Interactions with Other Medicines and Products

Stacer can interact with a wide range of other medicines by affecting how the body processes them. Official regulatory information identifies that Stacer is a potent inducer (accelerator) of several major metabolic enzymes, including Cytochrome P450 (CYP) enzymes (such as CYP3A4, CYP2C9, and CYP2D6), and certain drug transporters (such as P-glycoprotein).

This induction can cause a significant decrease in the levels and effectiveness of many co-administered medicines that are metabolized or transported by these pathways. Consequently, patients taking Stacer may require adjustments to the dosage or selection of alternative therapy for other concurrent medications.

Key interaction domains include:

  • Medicines metabolized by CYP Enzymes: The effectiveness of many co-administered substrates may be reduced due to increased metabolism.
  • Medicines transported by P-glycoprotein: The exposure of certain medicines (e.g., specific immunosuppressants or statins) transported by P-gp can be lowered.
  • Hormonal Contraceptives: Stacer significantly reduces the effectiveness of all hormonal contraceptives, including oral pills, patches, and rings. A mandatory requirement is to substitute hormonal methods with reliable non-hormonal contraception before starting, during, and after treatment to prevent unintended pregnancy.

Patients on Stacer should be carefully monitored for a possible loss of therapeutic effect from any co-administered medicine that is a substrate of these affected enzymes or transporters.

Mechanism of Action

How Stacer Works — Mechanism of Action

Stacer is an alpha2-adrenergic receptor (alpha2-AR) agonist that modulates signaling within the noradrenergic pathway. Its primary mechanistic action is the direct activation of alpha2-ARs, particularly the presynaptic subtypes found in the central nervous system (CNS), including the Locus Coeruleus (LC). This binding mimics norepinephrine, triggering a negative feedback loop that drastically reduces the subsequent neuronal release of norepinephrine (NE). This attenuation of NE signaling within the CNS leads to the physiological consequences of decreased arousal and sedation due to suppressed central sympathetic outflow.

The drug's action also extends to the autonomic and spinal systems. By reducing central sympathetic drive, Stacer modulates peripheral sympathetic nerve signals that regulate the cardiovascular system. This leads to the adjustments of slower heart rate (bradycardia) and decreased blood pressure (hypotension). Simultaneously, alpha2-AR activation in the spinal cord's dorsal horn potentiates the descending inhibitory pathways, increasing the blockade of nociceptive signal transmission and resulting in antinociception (pain-blocking).

Dosage and Administration Information

Ranitidine Hydrochloride, commonly marketed as Stacer, is administered via the oral route (tablets, capsules, syrup, or effervescent forms) and the parenteral route, which includes intravenous (IV) and intramuscular (IM) injection. Parenteral administration is typically designated for use in supervised clinical environments.

Oral dosing regimens are standardized based on the treatment scenario. For active ulcer treatment, the standard adult dose is 150 mg twice daily or 300 mg once daily, often taken at bedtime. Maintenance therapy for ulcer prevention commonly involves a dose of 150 mg taken once daily. Stacer can be administered with or without food, as its absorption is not significantly affected by meals.

Acute ulcer therapy generally runs for 4 to 8 weeks, while over-the-counter (OTC) use for self-treatment is limited to a maximum of 14 consecutive days. Patients with renal impairment (creatinine clearance <50 mL/min) require a dose adjustment to 150 mg every 24 hours to manage excretion. Pediatric dosing is determined using a weight-based (mg/kg) regimen.

Patients using effervescent forms must ensure the product is fully dissolved in water before ingestion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stacer

Evidence for Use in Healing Duodenal and Gastric Ulcers

The research exploring the use of Stacer for ulcers primarily consists of numerous short-term, controlled trials and subsequent meta-analyses. These research scenarios focused on conditions characterized by acute or disruptive episodes where symptoms may vary in intensity. Studies monitored outcomes by evaluating the outcomes linked to inflammatory or irritative states, typically measured by endoscopy over defined intervals of four to eight weeks, and outcomes related to patient-reported outcomes describing perceived discomfort.

Findings from the available studies describe patterns observed in the studied adult populations. Research also explored the longer-term assessment of these conditions, with trials monitoring patient groups for up to a year to report on the patterns of recurrence. However, long-term outcomes for ulcer patients extending beyond the 12-month maintenance period are not fully established.


Evidence for Use in Gastroesophageal Reflux Disease (GERD)

Research has explored whether Stacer was associated with changes in GERD and related mucosal irritation (esophagitis) through short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, with outcomes capturing phases of heightened symptom activity.

The studies report measurements of changes in symptoms in the observed adult populations. The research highlights changes measured during the short study period, with findings describing patterns in patient-reported outcomes describing perceived discomfort. Studies describe patterns related to the observed mucosal states on endoscopy following the short-term use periods. Data for long-term outcomes and the sustained resolution of GERD symptoms beyond the typical 6-month trial duration are still emerging.


Studies in Specific Patient Populations and Uncertainties

Stacer was evaluated in specific groups, including pediatric populations (children and adolescents) with GERD symptoms and older adults in ulcer trials. These studies were used in research exploring how symptoms change over time and findings describe group patterns related to these specific age cohorts.

Data for certain groups, such as specific rare hypersecretory conditions like Zollinger-Ellison Syndrome, remain insufficient, and the evidence quality varies across studies due to the use of small sample sizes. There is limited information for long-term outcomes following many years of use, and research is ongoing in various areas of comparative effectiveness against newer therapeutic classes. Evidence highlights what is known — and what is still uncertain — about the full range of long-term patient outcomes.

Key Studies & References

  1. Ranitidine use in pediatrics: current evidence-based review and recommendations
  2. Ranitidine Tablets, USP (Official Drug Label/Monograph)

Frequently Asked Questions (FAQ)

Common questions about Stacer (FAQ)


Q: Does Stacer interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Official regulatory documents describe that Stacer can influence how the body processes various co-administered medicines. While the labeling does not highlight specific major issues with common non-prescription pain relievers like ibuprofen or acetaminophen, the overall effect of Stacer on metabolism is a factor that is noted for clinical consideration when assessing new concurrent products.

Q: Are there any known interactions between Stacer and common vitamins or herbal supplements?

A: Official product information warns that Stacer has the potential to influence the metabolism and transport of various substances in the body. Patients are advised to inform their healthcare provider about all products they are using, including any vitamins and herbal supplements. This is done so that any potential interactions can be identified and evaluated before treatment begins.

Q: What are the described signs of a potential allergic reaction to Stacer?

A: Official information describes severe allergic reactions (anaphylaxis) as very rare but serious adverse events. Documented signs can include symptoms like hives, swelling of the face, lips, tongue, or throat, or difficulty breathing. If these signs occur, immediate clinical attention is warranted.

Q: Is Stacer available to purchase over the counter or is it prescription-only?

A: Stacer is available in different formulations. Some are sold without a prescription for limited, short-term self-treatment of certain conditions, with usage strictly limited to a specific number of days. Other formulations, often higher strength or injection forms, require a prescription from a licensed healthcare provider.

Q: Is Stacer recommended to be taken at a specific time of day?

A: Official documentation describes various dosing regimens. It is mentioned that the once-daily dose for certain treatment scenarios is commonly taken at bedtime. Other dosing schedules, such as those taken twice daily, may not carry a specific time recommendation in the regulatory documents.

Q: Does Stacer cause any major long-term side effects according to official documents?

A: Official research evidence for Stacer has monitored patients in long-term maintenance trials for up to one year to assess patterns of recurrence. Information regarding patient outcomes that extends beyond this initial long-term period is generally described as not fully established in the available regulatory documents.

Q: How long after starting Stacer should a patient expect to notice an initial effect?

A: Regulatory information indicates that the acid-reducing action of Stacer begins quickly. Official information indicates that the onset of this effect typically occurs within an hour of administration.

Q: What is the typical half-life of Stacer in the body?

A: Official pharmacological data describes the elimination half-life of Stacer. In individuals with normal kidney function, this half-life—the time it takes for the amount of drug in the body to be reduced by half—is typically between 2 to 3 hours.

Q: Is Stacer classified as a controlled substance?

A: According to federal drug schedules and similar international regulations, Stacer is not classified as a controlled substance. This means it has not been associated with drug abuse or the potential for physical dependence by regulatory agencies.

Q: Are there any specific safety warnings regarding driving or operating machinery while taking Stacer?

A: Regulatory documents note the need for caution regarding the ability to drive or operate complex machinery. This warning is due to the potential for reported adverse effects, which can include dizziness, reversible mental confusion, or blurred vision.

Q: How long does the primary beneficial effect of one Stacer dose typically last?

A: Regulatory information describes the duration of acid secretion control following a single dose. The primary beneficial effect of reducing stomach acid typically lasts for approximately 8 to 12 hours.

Q: Does Stacer affect or disrupt sleep patterns?

A: The regulatory profile notes that certain very rare side effects, such as reversible mental confusion and hallucinations, have been documented. These effects are primarily observed in specific populations, such as the severely ill or older patients, and could potentially impact rest and sleep.

Q: Can Stacer tablets be crushed or split in half?

A: Official regulatory instructions specify that effervescent forms must be completely dissolved in water before ingestion. For oral tablets, the documents generally describe them as being swallowed whole, unless the tablet is explicitly marked as scored to indicate it can be broken.

Q: Does Stacer lose its effectiveness after several years of continuous use?

A: Official research evidence examines patient groups over long periods, reporting on patterns of recurrence following treatment. This data implies that potential changes in the body's response over several years of continuous use are a clinical consideration that has been monitored in studies.

Q: What does the official package insert advise about how to handle a missed Stacer dose?

A: Official instructions included in the package insert typically describe general procedures for handling a missed dose, such as taking it upon remembering unless the next dose is due soon.

Q: Does Stacer have any known side effects that affect vision?

A: Official adverse event reporting for Stacer includes rare reports of side effects that affect vision. These have been documented as involving visual changes, such as blurred vision, which are typically described as reversible.

Q: Can Stacer be safely taken with common antacids?

A: Official information indicates that certain types of common antacids may interfere with the body's ability to properly absorb Stacer. For this reason, regulatory materials may recommend a specific time interval between taking Stacer and taking the antacid product.

Q: What is the full time frame for seeing the maximum beneficial effect of Stacer?

A: The time frame to achieve the full beneficial effect varies depending on the condition being addressed. For the treatment of active ulcers, regulatory documents define the required treatment duration as generally running for 4 to 8 weeks to achieve the desired therapeutic outcome.

Q: Does Stacer work right away, or does it take time to build up in the system?

A: Regulatory information describes two phases of effect. The acid-reducing action has a rapid onset, typically beginning within an hour. However, achieving the full therapeutic benefit—such as the healing of irritated tissues—requires adherence to the defined treatment duration of several weeks.

Q: Can men and women use Stacer for the same reasons?

A: The official indications for use, as described in regulatory documents, apply uniformly to the adult population. Stacer is prescribed for the same approved reasons for both men and women.

Q: What were the results of Stacer compared to a placebo in major clinical trials?

A: Research findings describe patterns observed in studied adult populations when compared to a control group, such as placebo. These trials focus on establishing efficacy by evaluating outcomes linked to inflammatory or irritative states, typically measured by endoscopy and patient-reported discomfort.

Q: Does Stacer usage affect the results of routine laboratory blood tests?

A: The official safety profile notes that rare but serious changes to blood counts have been reported, such as leucopenia (a reduction in white blood cells). If these events occur, they may be reflected in the results of routine laboratory blood tests.

Q: Does Stacer carry a Black Box Warning in its regulatory labeling?

A: The official labeling for Stacer does not include a Black Box Warning. This classification represents the strongest warning that the Food and Drug Administration (FDA) requires to alert the public and prescribers about potential serious adverse effects.

Q: Is Stacer considered habit-forming or does it have potential for dependence?

A: Regulatory information has examined the potential for Stacer to cause dependence or be subject to abuse. Official documents confirm that Stacer has not been associated with drug abuse or the potential for physical dependence.

Q: Is Stacer considered safe to use while breastfeeding?

A: Official documents indicate that Stacer is known to be excreted in human milk. Because of this, a decision regarding the continuation of the drug or the cessation of nursing is described as necessary.

How should Stacer be stored and disposed of?

Storage and Handling Requirements

The regulatory storage conditions for ranitidine hydrochloride products were historically defined as Controlled Room Temperature, typically 20 C to 25 C. The product must be protected from excess heat and moisture and should be stored in the original container, which must be tightly closed.

Mandatory Disposal Instructions

Official disposal guidance for ranitidine (Stacer) supersedes standard storage rules due to the potential for N-Nitrosodimethylamine (NDMA) impurity levels to increase over time, especially when exposed to higher temperatures. Government authorities requested the immediate withdrawal of all products from the market.

  • Do not return the medicine to a drug take-back location.
  • Disposal must occur at home by mixing the unused product with an unappealing substance (such as dirt or used coffee grounds) and placing the mixture in a sealed bag before discarding it in the household trash.
  • Do not flush the product down the toilet or pour it down a sink.
  • The medicine must always be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stacer found in:

A-Z Index: